ENTITY
Peijia Medical

Peijia Medical (9996 HK)

82
Analysis
Health Care • China
Peijia Medical is a China-based company specializing in the research, development, and manufacturing of high-end interventional medical devices. It provides comprehensive treatment solutions for structural heart diseases, including transcatheter aortic valve replacement (TAVR) systems, and neurovascular diseases with various neurointerventional devices. The company was founded in 2012 and is headquartered in Suzhou, China.
more
•21 Jan 2021 18:57

Venus Medtech (启明医疗) & Peijia Medical (沛嘉医疗) Placement - Take Your Pick

Venus MedTech (2500 HK) is looking to raise up to US$187m in its primary placement. At the same time, Peijia Medical (9996 HK) is looking to raise...

Share
•20 Jan 2021 01:22

MicroPort CardioFlow IPO Initiation: To Save a Life

MicroPort is pre-marketing for an HK IPO to raise $300 million. With a large addressable market opportunity and VitaFlow’s potentially best-in...

Logo
955 Views
Share
•13 Jan 2021 13:49

MicroPort Cardioflow (微创心通) Pre-IPO: Strong Sales Ramp-Up Despite Being Late in Market

The company's first-generation TAVR, VitaFlow, has decent clinical data in terms of efficacy and safety. It was launched two years behind VenusA...

Logo
628 Views
Share
•10 Jan 2021 01:26

Microport Cardioflow: Winning in TAVR

We provide our initial thoughts on the proposed listing of medical device (TAVR) company MicroPort Cardioflow on the HKEX.

Share
•16 Dec 2020 09:23

Pre-IPO MicroPort CardioFlow - A Better Candidate of the TAVR Market in China?

This article analyzed the market potential of TAVR in China, competition pattern of key players, financial position of MicroPort CardioFlow and...

Logo
662 Views
Share
x